Peter Høngaard Andersen has extensive experience in drug discovery and development from companies such as Novo Nordisk and Lundbeck, where he last held the position as EVP and Head of Research and corporate patents. He is the founder of Innovation Fund Denmark and was the CEO until May 2019, and he was chairing the Innovative Medicines Initiative (IMI) from 2009–2014. He is the co-founder of Acadia Pharmaceuticals, Zealand Pharma, Glycom, Epitherapeutics, Prexton Therapeutics, and since 2018 the Chairman of Scandion Oncology. Peter Høngaard Andersen holds a degree in chemistry, biochemistry, and medicine.
Professor Edvinsson is a leading expert in the field of cerebral circulation. He is world-recognized for his work on vascular innervation and receptor regulation. His extensive research is a major contributor to the current knowledge about the roles of the cerebral vasculature in health and diseases such as stroke and primary headaches. He is the director and founder of the Glostrup Science Park at Copenhagen University Hospital and Professor in Internal Medicine, Faculty of Medicine, and senior consultant in internal medicine, University Hospital SUS Lund. He has received numerous honors and awards including Director and President, International Headache Society; Member, Steering Board, European Headache Federation; Honorary Doctorate, University of Xián, China; Lifetime Achievement Award, American Headache Society. He was recently awarded the Lundbeck Foundation’s prestigious Brain Prize 2021.
Tore Duvold holds a PhD degree in chemistry from Université Louis Pasteur. He has extensive experience in the biotech and the pharmaceutical industries including SVP and head of research, early development and patent at LEO Pharma, CEO and co-founder of Aker Biopharma, CEO of Coegin Pharma. He recently served as EVP and later CEO of Innovation Fund Denmark. He is also associated partner at Copenhagen Institute for Futures Studies and has comprehensive experience in university collaborations.
Niclas Lundqvist holds a Degree of Master of Laws (LL. M.). He has previously been active in the stockbroker adviser firm ATS Finans AB (Sedermera Fondkommission) and at the law firm Advokatbolaget Wiklund Gustavii. He has long experience from operational board work as board member both of companies listed on the Swedish stock exchange and in a securities company under the supervision of the Swedish Financial Supervisory Authority.
Jesper Kihl holds a Master of Science in Chemical Engineering from Technical University of Denmark and has more than 40 years’ experience within life science and medtech, mostly from leading positions. He spent 14 years at LEO Pharma A/S, in positions such as Vice President Global Regulatory Affairs. Prior to that, he served at Novo Nordisk for 22 years, active in manufacturing, quality, development, marketing and logistics. Jesper Kihl is and has been a member of several Advisory Boards, including for Biogenity, and works with funds, universities and other institutions.
Stine Larsen holds a PhD in neurobiology, and has 10 years of experience in drug discovery as well as 15 years of experience in drug development from Lundbeck, ALK and Klifo. She has primarily worked within the field of neurodegenerative disorders in both drug discovery and drug development, with experience throughout the whole value chain from target discovery to filing a market authorization application, including experience in Phase I, II, and III. At ALK, Stine developed and executed a large pediatric study in allergic asthma. At Klifo, she was the head of the Pharmacovigilance Department. Stine Larsen’s passion is to use her molecular understanding of disease biology and the drug being tested as the basis for designing clinical development programs, with a view to highlighting drug efficacy.
c/o Medicon Village
223 81 Lund, Sweden
Tore Duvold, CEO